ArticleCEN case reports2026
Tips of family history taking in diagnosing Alport syndrome: a report of six cases.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alport syndrome (AS) is a hereditary kidney disease characterized by progressive renal dysfunction, sensorineural hearing loss, and ocular abnormalities. This report describes six AS cases diagnosed by a single physician, focusing on diagnostic processes and genetic findings. Detailed family history was crucial in all six cases for raising AS suspicion, even when clinical and histological findings were inconclusive. If urinalysis shows abnormalities, nephritis should be considered first. In addition, hereditary kidney disease should be included among the differential diagnoses. Suspecting hereditary kidney disease is the first step, and obtaining thorough family history is essential, not only at the initial consultation, but also during follow-up. When renal biopsy (RB) results or clinical findings suggest hereditary kidney disease, or if family members with kidney disease are identified, the possibility of AS should be re-evaluated. Pedigree creation can help identify additional affected relatives, and genetic testing should be pursued when hereditary kidney disease is strongly suspected. Confirmed AS diagnosis through genetic testing facilitates appropriate management, including renin-angiotensin system (RAS) inhibitors use, while avoiding unnecessary immunosuppressive therapy. These measures may improve patient outcomes and long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.